Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma

References

• Eichenauer DA, Engert A. Advances in the treatment of Hodgkin lymphoma. Int J Hematol. 2012;96(5):535–543. doi:10.1007/s12185-012-1199-223054655
   PubMed Web of Science ®Google Scholar
• Makita S, Maruyama D, Maeshima AM, et al. Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. Int J Hematol. 2016;104(2):236–244. doi:10.1007/s12185-016-2007-127086350
   PubMed Web of Science ®Google Scholar
• Minn AY, Riedel E, Halpern J, et al. Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma. Br J Haematol. 2012;159(3):329–339. doi:10.1111/bjh.1203822966754
   PubMed Web of Science ®Google Scholar
• Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531–2533. doi:10.3109/10428194.2013.79886823617324
   PubMed Web of Science ®Google Scholar
• Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65–67. doi:10.1038/299065a07110326
   PubMed Web of Science ®Google Scholar
• Stein H, Gerdes J, Schwab U, et al. Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer. 1982;30(4):445–459. doi:10.1002/ijc.29103004116754630
   PubMed Web of Science ®Google Scholar
• Watanabe M, Itoh K, Togano T, et al. Ets-1 activates overexpression of JunB and CD30 in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. Am J Pathol. 2012;180(2):831–838. doi:10.1016/j.ajpath.2011.10.00722107829
   PubMed Web of Science ®Google Scholar
• Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10(6):457–470. doi:10.1006/smim.1998.01569826579
   PubMed Web of Science ®Google Scholar
• Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124(19):2983–2986. doi:10.1182/blood-2014-07-58495325224410
   PubMed Web of Science ®Google Scholar
• Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81–e82. doi:10.3324/haematol.2013.08491323716537
   PubMed Web of Science ®Google Scholar
• Ito Y, Makita S, Tobinai K. Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019;19(3):197–209. doi:10.1080/14712598.2019.157274630658046
   PubMed Web of Science ®Google Scholar
• Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, Phase 3 trial. Lancet. 2019;393(10168):229–240. doi:10.1016/S0140-6736(18)32984-230522922
   PubMed Web of Science ®Google Scholar
• Higuchi M, Matsuda T, Mori N, et al. Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation. Retrovirology. 2005;2:29. doi:10.1186/1742-4690-2-2915876358
   PubMed Web of Science ®Google Scholar
• Pongpruttipan T, Sukpanichnant S, Assanasen T, et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol. 2012;36(4):481–499. doi:10.1097/PAS.0b013e31824433d822314189
   PubMed Web of Science ®Google Scholar
• Makita S, Tobinai K. Clinical features and current optimal management of natural killer/T-cell lymphoma. Hematol Oncol Clin North Am. 2017;31(2):239–253. doi:10.1016/j.hoc.2016.11.00728340876
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715–2724. doi:10.1182/blood-2012-10-46184823343832
   PubMed Web of Science ®Google Scholar
• Campuzano-Zuluaga G, Cioffi-Lavina M, Lossos IS, Chapman-Fredricks JR. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. Leuk Lymphoma. 2013;54(11):2405–2411. doi:10.3109/10428194.2013.77840723432725
   PubMed Web of Science ®Google Scholar
• Slack GW, Steidl C, Sehn LH, Gascoyne RD. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Br J Haematol. 2014;167(5):608–617. doi:10.1111/bjh.1308525135752
   PubMed Web of Science ®Google Scholar
• Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a Phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–1402. doi:10.1182/blood-2014-09-59876325573987
   PubMed Web of Science ®Google Scholar
• Durkop H, Foss HD, Eitelbach F, et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol. 2000;190(5):613–618. doi:10.1002/(SICI)1096-9896(200004)190:5<613::AID-PATH559>3.0.CO;2-010727988
   PubMed Web of Science ®Google Scholar
• Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25(19):2764–2769. doi:10.1200/JCO.2006.07.897217515574
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171–179. doi:10.1111/j.1365-2141.2009.07740.x19466965
   PubMed Web of Science ®Google Scholar
• Falini B, Bolognesi A, Flenghi L, et al. Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immunotoxin. Lancet. 1992;339(8803):1195–1196. doi:10.1016/0140-6736(92)91135-U1349939
   PubMed Web of Science ®Google Scholar
• Matthey B, Borchmann P, Schnell R, et al. Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA’ against human lymphomas in vivo. Int J Cancer. 2004;111(4):568–574. doi:10.1002/ijc.2027815239135
   PubMed Web of Science ®Google Scholar
• Schnell R, Staak O, Borchmann P, et al. A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin’s and non-Hodgkin’s lymphoma. Clin Cancer Res. 2002;8(6):1779–1786.12060617
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–784. doi:10.1038/nbt83212778055
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–1465. doi:10.1182/blood-2003-01-003912714494
   PubMed Web of Science ®Google Scholar
• King HD, Dubowchik GM, Mastalerz H, et al. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxy triethylene glycol chains. J Med Chem. 2002;45(19):4336–4343. doi:10.1021/jm020149g12213074
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–1821. doi:10.1056/NEJMoa100296521047225
   PubMed Web of Science ®Google Scholar
• Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18(1):248–255. doi:10.1158/1078-0432.CCR-11-142522080439
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–2189. doi:10.1200/JCO.2011.38.041022454421
   PubMed Web of Science ®Google Scholar
• Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–1566. doi:10.1182/blood-2016-02-69985027432875
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–2071. doi:10.1016/S0140-6736(02)08938-912086759
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–1054. doi:10.1016/0140-6736(93)92411-L8096958
   PubMed Web of Science ®Google Scholar
• Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003;2003(1):225–247. doi:10.1182/asheducation-2003.1.225
   Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–1862. doi:10.1016/S0140-6736(15)60165-925796459
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642. doi:10.1182/blood-2018-07-86164130266774
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934–4937. doi:10.1182/blood-2010-05-28275620733154
   PubMed Web of Science ®Google Scholar
• Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. Haematologica. 2012;97(7):1073–1079. doi:10.3324/haematol.2011.05605122271893
   PubMed Web of Science ®Google Scholar
• Akhtar S, Al-Sugair AS, Abouzied M, et al. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT. Bone Marrow Transplant. 2013;48(12):1530–1536. doi:10.1038/bmt.2013.8823749108
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol. 2002;13(10):1628–1635. doi:10.1093/annonc/mdf22112377653
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–623. doi:10.1182/blood.V97.3.61611157476
   PubMed Web of Science ®Google Scholar
• Aparicio J, Segura A, Garcerá S, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999;10(5):593–595. doi:10.1023/A:102645483134010416011
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071–1079. doi:10.1093/annonc/mdm09017426059
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Nagy T, Pintilie M, et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer. 2006;106(2):353–360. doi:10.1002/cncr.2158716329112
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Schöder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284–292. doi:10.1016/S1470-2045(15)70013-625683846
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136–2140. doi:10.1016/j.bbmt.2015.07.01826211987
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019;30(4):612–620. doi:10.1093/annonc/mdz00930657848
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Mooij H, Zijlstra J, et al. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the HOVON/LLPC Transplant BRaVE study. Haematologica. 2019;104(4):e151–e153. doi:10.3324/haematol.2018.19689930381303
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Zijlstra J, Plattel WJ, et al. Combining brentuximab vedotin with DHAP as salvage treatment in relapsed/refractory Hodgkin lymphoma: the phase II HOVON/LLPC transplant BRaVE study. Blood. 2018;132(Suppl_1):2923. doi:10.1182/blood-2018-99-112235
   Google Scholar
• Cassaday RD, Fromm J, Cowan AJ, et al. Radiographic and high-throughput sequencing (HTS)-based response assessment after brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed/refractory (Rel/Ref) classical Hodgkin lymphoma (cHL): updated results of a phase I/II trial. Blood. 2017;130(Suppl_1):2806.
   Google Scholar
• LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40–48. doi:10.1182/blood-2017-11-81518329703778
   PubMed Web of Science ®Google Scholar
• Cole PD, McCarten KM, Pei Q, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin’s lymphoma (AHOD1221): a Children’s Oncology Group, multicentre single-arm, Phase 1-2 trial. Lancet Oncol. 2018;19(9):1229–1238. doi:10.1016/S1470-2045(18)30426-130122620
   PubMed Web of Science ®Google Scholar
• Labrador J, Cabrero-Calvo M, Pérez-López E, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma. Ann Hematol. 2014;93(11):1745–1753. doi:10.1007/s00277-014-2114-024863692
   PubMedGoogle Scholar
• Martínez C, Díaz-López A, Rodriguez-Calvillo M, et al. Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haematol. 2016;174(6):859–867. doi:10.1111/bjh.1413327185197
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31(4):456–460. doi:10.1200/JCO.2012.45.330823248254
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018;19(2):257–266. doi:10.1016/S1470-2045(17)30912-929276022
   PubMed Web of Science ®Google Scholar
• Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183–1194. doi:10.1182/blood-2017-10-81122429229594
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Advani R, Bartlett NL, et al. Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase I/II study. Blood. 2019;134(Suppl. 1):238. doi:10.1182/blood-2019-122576
   Google Scholar
• Gardai SJ, Epp A, Law C-L. Brentuximab vedotin-mediated immunogenic cell death. Cancer Res. 2015;75(15Suppl):2469. doi:10.1158/0008-5472.CAN-14-3569
   Google Scholar
• Cao A, Heiser R, Law C-L, Gardai SJ. Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses. Cancer Res. 2016;76(14Suppl):4914. doi:10.1158/0008-5472.CAN-16-0584
   Google Scholar
• Nagai H. Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy. Jpn J Clin Oncol. 2015;45(2):137–145. doi:10.1093/jjco/hyu20425489004
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746–3752. doi:10.1200/JCO.2007.11.652517646666
   PubMed Web of Science ®Google Scholar
• Press OW, Li H, Schöder H, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: southwest Oncology Group S0816. J Clin Oncol. 2016;34(17):2020–2027. doi:10.1200/JCO.2015.63.111927069074
   PubMed Web of Science ®Google Scholar
• Stephens DM, Li H, Schöder H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach for stage III/IV Hodgkin lymphoma. Blood. 2019;134(15):1238–1246. doi:10.1182/blood.201900071931331918
   PubMed Web of Science ®Google Scholar
• Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018;36(5):454–462. doi:10.1200/JCO.2017.75.254329360414
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374:2419–2429. doi:10.1056/NEJMoa151009327332902
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Broccoli A, Gioia DM, et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016;34(12):1376–1385. doi:10.1200/JCO.2015.63.069926884559
   PubMed Web of Science ®Google Scholar
• Anderson RA, Remedios R, Kirkwood AA, et al. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin’s lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. Lancet Oncol. 2018;19(10):1328–1337. doi:10.1016/S1470-2045(18)30500-X30220622
   PubMed Web of Science ®Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–1356. doi:10.1016/S1470-2045(13)70501-124239220
   PubMed Web of Science ®Google Scholar
• Connors JM, Ansell SM, Fanale M, Park SI, Younes A. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood. 2017;130(11):1375–1377. doi:10.1182/blood-2017-05-78467828733323
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–344. doi:10.1056/NEJMoa170898429224502
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–4554. doi:10.1200/JCO.2008.19.882019704068
   PubMed Web of Science ®Google Scholar
• Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–1799. doi:10.1016/S0140-6736(11)61940-522480758
   PubMed Web of Science ®Google Scholar
• Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(10):943–952. doi:10.1016/S1470-2045(13)70341-323948348
   PubMed Web of Science ®Google Scholar
• Engert A, Goergen H, Markova J, et al. Reduced-intensity chemotherapy in patients with advanced-stage Hodgkin lymphoma: updated results of the open-label, international, randomised phase 3 HD15 trial by the German Hodgkin study group. HemaSphere. 2017;1(1):e5. doi:10.1097/HS9.000000000000000531723734
   PubMed Web of Science ®Google Scholar
• Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–212. doi:10.1056/NEJMoa110034021774708
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Plütschow A, Kreissl S, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017;18(12):1680–1687. doi:10.1016/S1470-2045(17)30696-429133014
   PubMed Web of Science ®Google Scholar
• Stark GL, Wood KM, Jack F, et al. Hodgkin’s disease in the elderly: a population-based study. Br J Haematol. 2002;119(2):432–440. doi:10.1046/j.1365-2141.2002.03815.x12406082
   PubMed Web of Science ®Google Scholar
• Levis A, Depaoli L, Bertini M, et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin’s disease patients. Haematologica. 1996;81(5):450–456.8952159
   PubMed Web of Science ®Google Scholar
• Roy P, Vaughan Hudson G, Vaughan Hudson B, Esteve J, Swerdlow AJ. Long-term survival in Hodgkin’s disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries. Eur J Cancer. 2000;36(3):384–389. doi:10.1016/S0959-8049(99)00267-110708941
   PubMed Web of Science ®Google Scholar
• Weekes CD, Vose JM, Lynch JC, et al. Hodgkin’s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol. 2002;20(4):1087–1093. doi:10.1200/JCO.2002.20.4.108711844834
   PubMed Web of Science ®Google Scholar
• Landgren O, Algernon C, Axdorph U, et al. Hodgkin’s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003;88(4):438–444.12681971
   PubMed Web of Science ®Google Scholar
• Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161(1):76–86. doi:10.1111/bjh.1222223356491
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798–2804. doi:10.1182/blood-2015-06-64433626377597
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood. 2017;130(26):2829–2837. doi:10.1182/blood-2017-06-78720029038340
   PubMed Web of Science ®Google Scholar
• Evens AM, Connors JM, Younes A, et al. Older patients with previously untreated classical Hodgkin lymphoma: a detailed analysis from the phase 3 ECHELON-1 study. Blood. 2018;132(Supplement1):1618. doi:10.1182/blood-2018-99-11217830045839
   PubMedGoogle Scholar
• Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018;36(30):3015–3022. doi:10.1200/JCO.2018.79.013930179569
   PubMed Web of Science ®Google Scholar
• Yasenchak CA, Bordoni R, Yazbeck V, et al. Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with Hodgkin lymphoma aged ≥60 years. Blood. 2019;134(Supplement1):237. doi:10.1182/blood-2019-124866
   Google Scholar
• Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32(12):1188–1194. doi:10.1200/JCO.2013.51.929824637998
   PubMed Web of Science ®Google Scholar
• MPE A, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–1794. doi:10.1200/JCO.2016.68.639428291393
   PubMed Web of Science ®Google Scholar
• Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640‐652. doi:10.1056/NEJMoa1000067
   Web of Science ®Google Scholar
• Sasse S, Bröckelmann PJ, Goergen H, et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017;35(18):1999–2007. doi:10.1200/JCO.2016.70.941028418763
   PubMed Web of Science ®Google Scholar
• Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol. 2019;37(31):2835–2845. doi:10.1200/JCO.19.0096431498753
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598–1607. doi:10.1056/NEJMoa140864825901426
   PubMed Web of Science ®Google Scholar
• Abramson JS, Arnason JE, LaCasce AS, et al. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019;134(7):606–613. doi:10.1182/blood.201900127231186274
   PubMed Web of Science ®Google Scholar
• Chen R, Hou J, Newman E, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14(6):1376–1384. doi:10.1158/1535-7163.MCT-15-003625840583
   PubMed Web of Science ®Google Scholar
• Al-Rohil RN, Torres-Cabala CA, Patel A, et al. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016;43(12):1161–1166. doi:10.1111/cup.1279727531242
   PubMed Web of Science ®Google Scholar
• Makita S, Maeshima AM, Taniguchi H, et al. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma. Int J Hematol. 2016;104(3):396–399. doi:10.1007/s12185-016-2018-y27169615
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Hong F, Ambinder R, et al. Extended follow-up of a phase I trial of ipilimumab, nivolumab and brentuximab vedotin in relapsed Hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412). Hematol Oncol. 2019;37(Suppl2):123–124. doi:10.1002/hon.83_2629
   Google Scholar
• Küppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer. 2009;9(1):15–27. doi:10.1038/nrc254219078975
   PubMed Web of Science ®Google Scholar
• Mathas S, Hartmann S, Küppers R. Hodgkin lymphoma: pathology and biology. Semin Hematol. 2016;53(3):139–147. doi:10.1053/j.seminhematol.2016.05.00727496304
   PubMed Web of Science ®Google Scholar
• Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma. 2007;48(7):1313–1319. doi:10.1080/1042819070141145817613759
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Fanale M, et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012;30(33):4161–4167. doi:10.1200/JCO.2012.42.522322965964
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, André M, Gastinne T, et al. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica. 2018;103(5):840–848. doi:10.3324/haematol.2017.18055429351986
   PubMed Web of Science ®Google Scholar
• Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320–324. doi:10.1002/ajh.2166420229590
   PubMed Web of Science ®Google Scholar
• Gopal AK, Fanale MA, Moskowitz CH, et al. Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma. Ann Oncol. 2017;28(5):1057–1063. doi:10.1093/annonc/mdx02828327905
   PubMed Web of Science ®Google Scholar
• Oki Y, Fanale M, Romaguera J, et al. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015;171(4):463–470. doi:10.1111/bjh.1360326213141
   PubMed Web of Science ®Google Scholar
• Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30(18):2197–2203. doi:10.1200/JCO.2011.38.135022547596
   PubMed Web of Science ®Google Scholar
• Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011;12(13):1222–1228. doi:10.1016/S1470-2045(11)70265-022033282
   PubMed Web of Science ®Google Scholar
• Batlevi CL, Kasamon Y, Bociek RG, et al. ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. Haematologica. 2016;101(8):968–975. doi:10.3324/haematol.2016.14240627151994
   PubMed Web of Science ®Google Scholar
• Walewski J, Paszkiewicz-Kozik E, Borsaru G, et al. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study. Leuk Lymphoma. 2019;60(3):675–684. doi:10.1080/10428194.2018.149212230160566
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24. doi:10.1186/1756-8722-7-2424642247
   PubMed Web of Science ®Google Scholar
• Fukuhara N, Yamamoto G, Tsujimura H, et al. Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study. Leuk Lymphoma. 2019:1–5. doi:10.1080/10428194.2019.1654100.
   Web of Science ®Google Scholar